What is Guardant Health's primary revenue driver, and how is it performing?

Guardant Health's primary revenue driver is its Oncology segment, which saw a 38% increase year-over-year to $219.1 million in Q2 2026, driven by higher test volumes. The Screening segment, driven by the Shield test, experienced exceptional growth of 257% to $52.9 million in Q2 2026, with test volumes more than tripling, indicating strong market adoption and expansion.

What is the company's profitability outlook based on this report?

The company continues to operate at a net loss, reporting $120.1 million for Q2 2026 and $232.2 million for the first six months of 2026. While revenue is growing significantly, substantial investments in research and development, along with a considerable increase in sales and marketing expenses, are contributing to these losses. Profitability is not expected in the immediate short term as the company prioritizes growth and market penetration.

What are the key financial risks or contingencies facing Guardant Health?

A significant financial risk is the ongoing intellectual property dispute with TwinStrand Biosciences, which resulted in a jury verdict against Guardant Health for $83.4 million in damages. The company estimates a potential loss range of $0 to $250 million for this matter, although they are appealing the decision and have seen positive developments in patent office reviews. Additionally, the company's substantial convertible senior notes ($1.5 billion outstanding) represent a significant long-term liability that will need to be managed upon maturity or conversion.

How is the company managing its liquidity and capital resources?

Guardant Health maintains a strong liquidity position with approximately $1.2 billion in cash, cash equivalents, and restricted cash as of June 30, 2026. This ample cash balance, combined with anticipated cash flows from operations, is believed to be sufficient to meet capital requirements for more than 12 months. The company may seek additional capital if needed for expansion, strategic investments, or other opportunities, though this could result in dilution to existing shareholders.

GH 10-Q Quarterly Report Q2 FY2026 — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-Q filed July 30, 2026. Cited figures are marked; the original filing is the authoritative source.

Guardant Health, Inc. reported strong revenue growth of 44% year-over-year for the second quarter of 2026, reaching $335.0 million^a, and 46% for the first six months, totaling $636.6 million.

This growth was primarily driven by a significant increase in test volumes across its oncology and, notably, its screening segment, with Shield screening test volume more than tripling. Despite this robust top-line performance, the company continued to incur substantial net losses, reporting $120.1 million^b for the quarter and $232.2 million for the first six months. These losses are a result of continued heavy investment in research and development, and a significant increase in sales and marketing expenses, up 59% and 60% for the respective periods, to support commercial expansion and product adoption.

The company's balance sheet shows a healthy cash position of $1.2 billion^c as of June 30, 2026, providing ample liquidity for continued operations and investment. However, investors should note the ongoing legal proceedings, particularly the intellectual property dispute with TwinStrand Biosciences, which resulted in a significant jury verdict against Guardant Health, with a potential loss estimated between $0 and $250 million. While the company is contesting this verdict and has favorable developments in USPTO reviews of the patents, this remains a material contingent liability.

02—Key points

Key Highlights

Revenue increased by 44% to $335.0 million for Q2 2026 and by 46% to $636.6 million for the first six months of 2026, year-over-year.
Significant growth in the screening segment, with Shield test volume increasing 257% for the quarter and 361% for the first six months.
Net loss for the quarter was $120.1 million and $232.2 million for the first six months of 2026, indicating continued investment in growth.
Sales and marketing expenses increased substantially by 59% for the quarter and 60% for the first six months, reflecting expanded commercial efforts.
The company maintained a strong liquidity position with $1.2 billion in cash, cash equivalents, and restricted cash as of June 30, 2026.
A contingent liability exists related to a patent infringement lawsuit, with a potential loss estimated between $0 and $250 million, although the company is appealing the verdict and has positive developments in patent office reviews.
FDA approval of the Guardant360 Liquid CDx test in Q2 2026 and Medicare coverage for the Shield blood test in August 2024 are key regulatory milestones.

03—Questions

Frequently Asked Questions

What is Guardant Health's primary revenue driver, and how is it performing?
Guardant Health's primary revenue driver is its Oncology segment, which saw a 38% increase year-over-year to $219.1 million in Q2 2026, driven by higher test volumes. The Screening segment, driven by the Shield test, experienced exceptional growth of 257% to $52.9 million in Q2 2026, with test volumes more than tripling, indicating strong market adoption and expansion.
What is the company's profitability outlook based on this report?
The company continues to operate at a net loss, reporting $120.1 million for Q2 2026 and $232.2 million for the first six months of 2026. While revenue is growing significantly, substantial investments in research and development, along with a considerable increase in sales and marketing expenses, are contributing to these losses. Profitability is not expected in the immediate short term as the company prioritizes growth and market penetration.
What are the key financial risks or contingencies facing Guardant Health?
A significant financial risk is the ongoing intellectual property dispute with TwinStrand Biosciences, which resulted in a jury verdict against Guardant Health for $83.4 million in damages. The company estimates a potential loss range of $0 to $250 million for this matter, although they are appealing the decision and have seen positive developments in patent office reviews. Additionally, the company's substantial convertible senior notes ($1.5 billion outstanding) represent a significant long-term liability that will need to be managed upon maturity or conversion.
How is the company managing its liquidity and capital resources?
Guardant Health maintains a strong liquidity position with approximately $1.2 billion in cash, cash equivalents, and restricted cash as of June 30, 2026. This ample cash balance, combined with anticipated cash flows from operations, is believed to be sufficient to meet capital requirements for more than 12 months. The company may seek additional capital if needed for expansion, strategic investments, or other opportunities, though this could result in dilution to existing shareholders.

04—Continue

← View all 10-Q filings